Literature DB >> 10469671

New antithrombotic and antiplatelet treatment.

K L Neuhaus1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10469671      PMCID： PMC1766503          DOI： 10.1136/hrt.82.2008.i8

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  9 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

Authors:  M Cohen; C Demers; E P Gurfinkel; A G Turpie; G J Fromell; S Goodman; A Langer; R M Califf; K A Fox; J Premmereur; F Bigonzi
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

2.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Authors:  W Klein; A Buchwald; S E Hillis; S Monrad; G Sanz; A G Turpie; J van der Meer; E Olaisson; S Undeland; K Ludwig
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

3.  Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.

Authors:  B Lindahl; P Venge; L Wallentin
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

Review 4.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Authors:  J Hirsh; T E Warkentin; R Raschke; C Granger; E M Ohman; J E Dalen
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

5.  Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial.

Authors:  J A Ambrose; O D Almeida; S K Sharma; S R Torre; J D Marmur; D H Israel; D E Ratner; M B Weiss; C E Hjemdahl-Monsen; R K Myler
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

6.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

Authors:  E M Antman
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

7.  Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

Authors:  K L Neuhaus; R von Essen; U Tebbe; A Jessel; H Heinrichs; W Mäurer; W Döring; D Harmjanz; V Kötter; E Kalhammer
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

8.  Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.

Authors: 
Journal:  Circulation       Date:  1993-01       Impact factor: 29.690

Review 9.  Platelet GPIIb-IIIa blockers.

Authors:  E J Topol; T V Byzova; E F Plow
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321
  9 in total
  1 in total

Review 1.  Regular review: treatment possibilities for unstable angina.

Authors:  A Manhapra; S Borzak
Journal:  BMJ       Date:  2000-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.